Tissue-type plasminogen activator (tPA) encoded by is a major mediator that promotes fibrinolysis and prevents thrombosis. Pathogenetic mutations in associated with venous thromboembolism have rarely been reported. Here, we report the first case of a homozygous point mutation c.
View Article and Find Full Text PDFBackground: Nearly 80% of patients with pancreatic cancer suffer from glucose intolerance or diabetes. Pancreatic cancer complicated by diabetes has a more immunosuppressive tumor microenvironment (TME) and is associated with a worse prognosis. The relationship between glucose metabolism and programmed cell death-Ligand 1 (PD-L1) is close and complex.
View Article and Find Full Text PDFThrombomodulin (TM) functions in coagulation, fibrinolysis and inflammation by its cofactor activity for protein C, thrombin-activatable fibrinolysis inhibitor (TAFI) activation and high mobility group box 1 (HMGB1) degradation induced by thrombin. It has been widely reported that mutations in TM are related to thromboembolic diseases but hardly in lectin domain. Here we report our findings about the functional deficiencies in TM caused by substitution of aspartate with tyrosine at residue 126.
View Article and Find Full Text PDFBackground: Congenital coagulation factor X (FX) deficiency is a rare bleeding disorder with an incidence of one in one million caused by mutations in the FX-coding gene(F10), leading to abnormal coagulation activity and a tendency for severe hemorrhage. Therefore, identifying mutations in FX is important for diagnosing congenital FX deficiency.
Results: Genetic analysis of the proband identified two single-base substitutions: c.
Expert Opin Emerg Drugs
June 2020